NanoViricides, Inc. (NASDAQ:NNVC) | WebDisclosure

Basculer en Français

11080	Companies
243102	Keywords
171244	Articles
130865	Press releases

Home
Companies
NanoViricides, Inc.

PRESS RELEASE

published on 05/26/2026 at 14:30, 3 months 29 days ago

In the Ebola Emergency, NV-387 is Ready to be Shipped to DRC, and It Compares Favorably as a Treatment for Ebola Versus Possible Options, Says NanoViricides
NanoViricides, Inc. announces potential treatment option for Ebola Bundibugyo virus strain, highlighting broad-spectrum antiviral drug candidate NV-387, superior to Remdesivir, ready for Phase II clinical trial

NanoViricides NV-387 Clinical Trial Antiviral Drug Ebola Bundibugyo
BRIEF

published on 05/19/2026 at 06:00, 4 months 5 days ago

NanoViricides Closes $2 Million Registered Direct Offering

Securities NanoViricides Investment Direct Offering Antivirals
BRIEF

published on 05/19/2026 at 06:00, 4 months 5 days ago

NanoViricides clôture une offre directe enregistrée de 2 millions de dollars

Investissement NanoViricides Titres Offre Directe Antiviraux
PRESS RELEASE

published on 05/19/2026 at 05:55, 4 months 5 days ago

NanoViricides Announces Closing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces closing of $2M direct offering. Exclusive placement agent D. Boral Capital LLC. SEC registration effective. NV-387, a revolutionary antiviral drug granted Orphan Drug Designation

NanoViricides NV-387 Direct Offering SEC Registration D. Boral Capital LLC
BRIEF

published on 05/18/2026 at 14:35, 4 months 6 days ago

NanoViricides Highlights NV-387 as a Potential Solution for Ebola Outbreak

NV-387 Antiviral Drug Pandemic Preparedness Ebola Outbreak Bundibugyo Strain
BRIEF

published on 05/18/2026 at 14:35, 4 months 6 days ago

NanoViricides met en avant le NV-387 comme solution potentielle à l'épidémie d'Ebola

NV-387 Médicament Antiviral Préparation Aux Pandémies Épidémie D'Ebola Souche Bundibugyo
PRESS RELEASE

published on 05/18/2026 at 14:30, 4 months 6 days ago

Ebola Global Health Emergency Needs a Broad-Spectrum Drug - NV-387 is a Strong Potential Candidate, Says NanoViricides
NanoViricides, Inc. highlights the urgent need for a broad-spectrum antiviral drug like NV-387 amid an Ebolavirus outbreak in DR Congo and Uganda. NV-387 holds promise as it targets sulfated proteoglycans crucial for viral attachment to cells

NanoViricides NV-387 Antiviral Drug Broad-spectrum Ebolavirus Outbreak
BRIEF

published on 05/15/2026 at 14:40, 4 months 9 days ago

NanoViricides Announces $2 Million Direct Offering

NanoViricides Securities Offering Direct Investment Institutional Investor Antiviral Technology
BRIEF

published on 05/15/2026 at 14:40, 4 months 9 days ago

NanoViricides annonce une levée de fonds directe de 2 millions de dollars

NanoViricides Investissement Direct Offre De Titres Investisseur Institutionnel Technologie Antivirale
PRESS RELEASE

published on 05/15/2026 at 14:35, 4 months 9 days ago

NanoViricides Announces Pricing of ~$2 Million Registered Direct Offering
NanoViricides, Inc. announces a registered direct offering of common shares and warrants to a fundamental institutional investor for gross proceeds of approximately US$2 million. D. Boral Capital LLC acts as the exclusive placement agent for the Offering

NanoViricides Securities Purchase Agreement Registered Direct Offering D. Boral Capital LLC Fundamental Institutional Investor

Accesswire

Published on 09/24/2026 at 22:01, 1 hour 35 minutes ago

Fermi Selects CBRE to Operate and Maintain Its First Data Center
Published on 09/24/2026 at 17:45, 5 hours 51 minutes ago

Jo-Jo Announces Resignation of Director
Published on 09/24/2026 at 14:55, 8 hours 41 minutes ago

Nextech3D.ai Surpasses $1 Million in New Customer Contract Value, Expands AI Software Portfolio with KATE and Grows Multi-Year Enterprise Agreements
Published on 09/24/2026 at 14:30, 9 hours 6 minutes ago

Solitario Resources CEO to Present at the 38th Annual Mining Forum Americas 2026 Conference
Published on 09/24/2026 at 14:00, 9 hours 36 minutes ago

Horizon Aircraft to Report First Quarter 2027 Results and Provide a Business Update on October 9, 2026

View all ACCESSWIRE

EQS Group

Published on 09/24/2026 at 20:29, 3 hours 6 minutes ago

EQS-Adhoc: HelloFresh SE expects revenue for Q3 2026 below market expectations and adjusts outlook for the financial year 2026
Published on 09/24/2026 at 19:00, 4 hours 36 minutes ago

HIAG provides a first-hand insight into its strategy and the added value it generates at its Capital Market Day
Published on 09/24/2026 at 18:40, 4 hours 55 minutes ago

EQS-Adhoc: Brockhaus Technologies AG launches public share buyback offer of approx. €90 million for up to 3,592,000 shares
Published on 09/24/2026 at 18:15, 5 hours 21 minutes ago

Epanko Value Engineering Identifies 20% Production Increase
Published on 09/24/2026 at 18:05, 5 hours 30 minutes ago

DCK Tools Showcases Expanded Outdoor Power Equipment Lineup at Salonvert 2026

Les Echos

Published on 09/24/2026 at 18:31, 5 hours 4 minutes ago

LNA SANTE : Mise à disposition du rapport financier semestriel 2026
Published on 09/24/2026 at 18:10, 5 hours 26 minutes ago

Financial statements - 30 june 2026
Published on 09/24/2026 at 18:00, 5 hours 36 minutes ago

GUILLEMOT CORPORATION: Availability of the interim financial report to June 30, 2026
Published on 09/24/2026 at 18:00, 5 hours 36 minutes ago

GUILLEMOT CORPORATION : Mise à disposition du rapport financier semestriel au 30 juin 2026
Published on 09/24/2026 at 18:00, 5 hours 36 minutes ago

i2S : Résultats 1er semestre 2026

View all LES ECHOS COMFI WIRE